Baoshan Gao1, Chunshu Rong, Fabrice Porcheray, Carolina Moore, Timothy C Girouard, Susan L Saidman, Waichi Wong, Yaowen Fu, Emmanuel Zorn. 1. 1 Department of Surgery, Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2 Transplant Center, The First Hospital of Jilin University, Changchun, China. 3 The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China. 4 Division of Nephrology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY. 5 Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Assessing the serum reactivity to HLA is essential for the evaluation of transplant candidates and the follow-up of allograft recipients. In this study, we look for evidence at the clonal level that polyreactive antibodies cross-reactive to apoptotic cells and multiple autoantigens can also react to HLA and contribute to the overall serum reactivity. METHODS: We immortalized B cell clones from the blood of 2 kidney transplant recipients and characterized their reactivity to self-antigens, apoptotic cells as well as native, denatured, and cryptic HLA determinants using enzyme-linked immunosorbent assay (ELISA), immunofluorescence, flow cytometry and Luminex assays. We also assessed the reactivity of 300 pretransplant serum specimens to HLA and apoptotic cells. RESULTS: We report here 4 distinct B cell clones cross-reactive to self and HLA class I. All 4 clones reacted to numerous HLA class I alleles but did not appear to target canonical "shared" epitopes. In parallel experiments, we observed a strong correlation between IgG reactivity to HLA and apoptotic cells in pretransplant serum samples collected from 300 kidney transplant recipients. Further analysis revealed that samples with higher reactivity to apoptotic cells displayed significantly higher class I percent panel-reactive antibodies compared to samples with low reactivity to apoptotic cells. CONCLUSIONS: We provide here (1) proof of principle at the clonal level that human polyreactive antibodies can cross-react to HLA, multiple self-antigens and apoptotic cells and (2) supportive evidence that polyreactive antibodies contribute to overall HLA reactivity in the serum of patients awaiting kidney transplant.
BACKGROUND: Assessing the serum reactivity to HLA is essential for the evaluation of transplant candidates and the follow-up of allograft recipients. In this study, we look for evidence at the clonal level that polyreactive antibodies cross-reactive to apoptotic cells and multiple autoantigens can also react to HLA and contribute to the overall serum reactivity. METHODS: We immortalized B cell clones from the blood of 2 kidney transplant recipients and characterized their reactivity to self-antigens, apoptotic cells as well as native, denatured, and cryptic HLA determinants using enzyme-linked immunosorbent assay (ELISA), immunofluorescence, flow cytometry and Luminex assays. We also assessed the reactivity of 300 pretransplant serum specimens to HLA and apoptotic cells. RESULTS: We report here 4 distinct B cell clones cross-reactive to self and HLA class I. All 4 clones reacted to numerous HLA class I alleles but did not appear to target canonical "shared" epitopes. In parallel experiments, we observed a strong correlation between IgG reactivity to HLA and apoptotic cells in pretransplant serum samples collected from 300 kidney transplant recipients. Further analysis revealed that samples with higher reactivity to apoptotic cells displayed significantly higher class I percent panel-reactive antibodies compared to samples with low reactivity to apoptotic cells. CONCLUSIONS: We provide here (1) proof of principle at the clonal level that human polyreactive antibodies can cross-react to HLA, multiple self-antigens and apoptotic cells and (2) supportive evidence that polyreactive antibodies contribute to overall HLA reactivity in the serum of patients awaiting kidney transplant.
Authors: J-P Sigle; J Thierbach; L Infanti; M Muriset; G Hunziker; K Chassot; C Niederhauser; P Gowland; A Holbro; K Sunic; A Buser; S Fontana Journal: Vox Sang Date: 2013-06-16 Impact factor: 2.144
Authors: B Gao; C Moore; F Porcheray; C Rong; C Abidoglu; J DeVito; R Paine; T C Girouard; S L Saidman; D Schoenfeld; B Levin; W Wong; N Elias; C Schuetz; I Rosales; Y Fu; E Zorn Journal: Am J Transplant Date: 2014-06-16 Impact factor: 8.086
Authors: F Porcheray; J W Fraser; B Gao; A McColl; J DeVito; I Dargon; Y Helou; W Wong; T C Girouard; S L Saidman; R B Colvin; A Palmisano; U Maggiore; A Vaglio; R N Smith; E Zorn Journal: Am J Transplant Date: 2013-08-06 Impact factor: 8.086
Authors: Luis E Morales-Buenrostro; Paul I Terasaki; Lluvia A Marino-Vázquez; Jar-How Lee; Nadim El-Awar; Josefina Alberú Journal: Transplantation Date: 2008-10-27 Impact factor: 4.939
Authors: Sarah B See; Benjamin S Mantell; Kevin J Clerkin; Bryan Ray; E Rodica Vasilescu; Charles C Marboe; Yoshifumi Naka; Susan Restaino; Paolo C Colombo; Linda J Addonizio; Maryjane A Farr; Emmanuel Zorn Journal: Am J Transplant Date: 2020-04-26 Impact factor: 8.086
Authors: Marianne Delville; Baptiste Lamarthée; Sylvain Pagie; Sarah B See; Marion Rabant; Carole Burger; Philippe Gatault; Magali Giral; Olivier Thaunat; Nadia Arzouk; Alexandre Hertig; Marc Hazzan; Marie Matignon; Christophe Mariat; Sophie Caillard; Nassim Kamar; Johnny Sayegh; Pierre-François Westeel; Cyril Garrouste; Marc Ladrière; Vincent Vuiblet; Joseph Rivalan; Pierre Merville; Dominique Bertrand; Alain Le Moine; Jean-Paul Duong Van Huyen; Anne Cesbron; Nicolas Cagnard; Olivier Alibeu; Simon C Satchell; Christophe Legendre; Emmanuel Zorn; Jean-Luc Taupin; Béatrice Charreau; Dany Anglicheau Journal: J Am Soc Nephrol Date: 2019-03-08 Impact factor: 10.121